There is information missing from the Competing Interests statement. The correct Competing Interests statement is as follows: N.A. was a consultant for Cepheid, and has licensed a biomarker for early detection of pancreas cancer to Cepheid (PATENT # 10167513). N.A also has grant funding from Astex Pharmaceuticals (GRANT # 120039). N.A. has served as a consultant to Johnson and Johnson, as an advisor to Celgene, and as a member of the Scientific Advisory Council to the No Stomach for Cancer Foundation. H.K. reviewed the manuscript; he is a scientific contributor and Vice President at Astex Inc. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Reference
- 1.Thakar M, Hu Y, Morreale M, Lerner L, Ying Lin W, Sen R, et al. (2018) A novel epigenetic modulating agent sensitizes pancreatic cells to a chemotherapy agent. PLoS ONE 13(6): e0199130 10.1371/journal.pone.0199130 [DOI] [PMC free article] [PubMed] [Google Scholar]